ArticleNature medicine2022
Performance of plasma phosphorylated tau 181 and 217 in the community.
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 350 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
350 citing papers in PubMed, 10 syntheses or guidelines pooled it, 468 citations in OpenAlex.
- Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2026Pooled it
- Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Blood-Based Tau as a Biomarker for Early Detection and Monitoring of Alzheimer's Disease: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review.European geriatric medicine · 2025Pooled it
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer's Disease: A Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Alzheimer's blood-based biomarkers, incident dementia, and interactions with age, APOE status, and hormone therapy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Trial
- Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity.JAMA network open · 2025Trial
- Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression.Molecular psychiatry · 2026Article
- Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers.Neurology · 2026Article
- APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid Positron-Emission Tomography: A Diagnostic Test Accuracy Meta-analysis.Neurology and therapy · 2026Article
- Plasma p-tau217 as a biomarker for Alzheimer's disease: diagnostic and prognostic value in clinical and population-based studies.Arquivos de neuro-psiquiatria · 2026Review
- Chronic kidney disease and cognitive decline: choroid plexus remodeling, glymphatic dysfunction, and alzheimer biomarker interpretation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
290 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but their performance in heterogeneous community-based populations is unclear. We examined P-tau181 and P-tau217 (n = 1,329, aged 30-98 years), in the population-based Mayo Clinic Study of Aging. Continuous, unadjusted plasma P-tau181 and P-tau217 predicted abnormal amyloid positron-emission tomography (PET) (area under the receiver operating characteristic curve (AUROC) = 0.81-0.86) and tau PET entorhinal cortex (AUROC > 0.80), but was less predictive of a tau PET temporal region of interest (AUROC < 0.70). Multiple comorbidities were associated with higher plasma P-tau181 and P-tau217 levels; the difference between participants with and without chronic kidney disease (CKD) was similar to the difference between participants with and without elevated brain amyloid. The exclusion of participants with CKD and other comorbidities affected the establishment of a normal reference range and cutpoints. Understanding the effect of comorbidities on P-tau181 and P-tau217 levels is important for their future interpretation in the context of clinical screening, diagnosis or prognosis at the population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.